Abstract
Current chemotherapy regimens against pancreatic cancer are met with little success as poor tumor vascularization significantly limits the delivery of oncological drugs. High-dose targeted drug delivery, through which a drug delivery vehicle releases a large payload upon tumor localization, is thus a promising alternative strategy against this lethal disease. Herein, we synthesize anti-carcinoembryonic antigen (CEA) half-antibody conjugated lipid-polymer hybrid nanoparticles and characterize their ligand conjugation yields, physicochemical properties, and targeting ability against pancreatic cancer cells. Under the same drug loading, the half-antibody targeted nanoparticles show enhanced cancer killing effect compared to the corresponding nontargeted nanoparticles.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 914-920 |
| Number of pages | 7 |
| Journal | Molecular pharmaceutics |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 7 2010 |
Keywords
- Carcinoembryonic antigen
- Half-antibody
- Lipid-polymer nanoparticles
- Pancreatic cancer
- Targeted drug delivery
ASJC Scopus subject areas
- Pharmaceutical Science
- Molecular Medicine
- Drug Discovery
Fingerprint
Dive into the research topics of 'Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS